Alvotech (ALVO) Change in Accured Expenses (2021 - 2026)
Alvotech (ALVO) posted Change in Accured Expenses of -$3.0 million for Q1 2026, up 79.65% on a QoQ basis from -$14.8 million in Q3 2025, and up 75.72% year-over-year from -$1.7 million in Q1 2025.
Alvotech (ALVO) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Alvotech's Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$3.0 million for Q1 2026.
- Quarterly Change in Accured Expenses rose 75.72% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.7 million (down 1.05% YoY) and the FY2023 annual result came in at -$5.2 million, up 75.77% from the prior year.
- Change in Accured Expenses was -$3.0 million for Q1 2026 at Alvotech, up from -$14.8 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $23.8 million in Q2 2024 and bottomed at -$25.0 million in Q3 2024.
- A 5-year average of -$2.8 million and a median of -$3.7 million in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 203.27% — and 2024, when it tumbled 714.92%.
- Alvotech's Change in Accured Expenses stood at $493000.0 in 2022, then soared by 159.63% to $1.3 million in 2023, then tumbled by 714.92% to -$7.9 million in 2024, then slumped by 88.08% to -$14.8 million in 2025, then soared by 79.65% to -$3.0 million in 2026.
- Business Quant data shows ALVO's Change in Accured Expenses at -$3.0 million in Q1 2026, -$14.8 million in Q3 2025, and $8.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Alvotech | 907.91 Mn | 907.91 Mn | 5.09 Mn | -3.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.01 Mn |
| Mar 31, 2026 | -3.01 Mn |
| Sep 30, 2025 | -14.80 Mn |
| Sep 30, 2025 | -14.80 Mn |
| Jun 30, 2025 | 8.49 Mn |
| Jun 30, 2025 | 8.49 Mn |
| Mar 31, 2025 | -12.41 Mn |
| Mar 31, 2025 | -12.41 Mn |
| Dec 31, 2024 | -7.87 Mn |
| Dec 31, 2024 | -7.87 Mn |
| Sep 30, 2024 | -25.04 Mn |
| Sep 30, 2024 | -25.04 Mn |
| Jun 30, 2024 | 23.82 Mn |
| Jun 30, 2024 | 23.82 Mn |
| Mar 31, 2024 | -7.14 Mn |
| Mar 31, 2024 | -7.14 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Jun 30, 2023 | 8.87 Mn |
| Jun 30, 2023 | 8.87 Mn |